Study Assessing Utility of a Clinical Questionnaire to Identify Subjects With Features of Both Asthma and Chronic Obstructive Pulmonary Disease (COPD)

PHASE2CompletedINTERVENTIONAL
Enrollment

1,215

Participants

Timeline

Start Date

January 1, 2015

Primary Completion Date

May 1, 2015

Study Completion Date

May 28, 2015

Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
PROCEDURE

Spirometry

Classification of respiratory diseases by Spirometry will be performed to differentiate subjects between Asthma only, ACOS, and COPD only. Spirometry obtained from measurements in the past 6 months is acceptable for purposes of this study. For subjects without spirometry in the past 6 months, spirometry will be performed to obtain pre- and post-bronchodilator Forced Expiratory Volume in one second (FEV1), Forced Vital Capacity (FVC) and reversibility

OTHER

ACOS clinical questionnaire

The 41-question questionnaire includes questions concerning the following: a) response to bronchodilator, b) disease progression, c) variations in symptom, d) atopic history, e) symptom triggers, f) vagal bias, g) burden of disease, h) symptom presentation, i) emotional aspects, and j) age of onset. In addition, two questions will capture patient perception of his/her respiratory disease and the physician's diagnosis

Trial Locations (42)

3680

GSK Investigational Site, Kyiv

4000

GSK Investigational Site, San Miguel de Tucumán

5500

GSK Investigational Site, Mendoza

5600

GSK Investigational Site, San Rafael

10117

GSK Investigational Site, Berlin

10119

GSK Investigational Site, Berlin

26505

GSK Investigational Site, Morgantown

28207

GSK Investigational Site, Charlotte

29303

GSK Investigational Site, Spartanburg

29340

GSK Investigational Site, Gaffney

29379

GSK Investigational Site, Union

29615

GSK Investigational Site, Greenville

29732

GSK Investigational Site, Rock Hill

30173

GSK Investigational Site, Hanover

45231

GSK Investigational Site, Cincinnati

49006

GSK Investigational Site, Dnipropetrovsk

49051

GSK Investigational Site, Dnipropetrovsk

60389

GSK Investigational Site, Frankfurt am Main

60596

GSK Investigational Site, Frankfurt am Main

61002

GSK Investigational Site, Kharkiv

61124

GSK Investigational Site, Kharkiv

63263

GSK Investigational Site, Neu-Isenburg

70584

GSK Investigational Site, Sunset

91786

GSK Investigational Site, Upland

92663

GSK Investigational Site, Newport Beach

97504

GSK Investigational Site, Medford

115409

GSK Investigational Site, Moscow

194354

GSK Investigational Site, Saint Petersburg

194356

GSK Investigational Site, Saint Petersburg

198216

GSK Investigational Site, Saint Petersburg

410028

GSK Investigational Site, Saratov

603126

GSK Investigational Site, Nizhny Novgorod

675000

GSK Investigational Site, Blagoveshchensk

C1028AAP

GSK Investigational Site, Ciudad Autonoma de Buenos Aires

S2000DBS

GSK Investigational Site, Rosario

C1426ABP

GSK Investigational Site, Buenos Aires

T4000IFL

GSK Investigational Site, San Miguel de Tucumán

04109

GSK Investigational Site, Leipzg

06682

GSK Investigational Site, Teuchern

02091

GSK Investigational Site, Kyiv

02232

GSK Investigational Site, Kyiv

03680

GSK Investigational Site, Kyiv

Sponsors

Lead Sponsor

All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT02302417 - Study Assessing Utility of a Clinical Questionnaire to Identify Subjects With Features of Both Asthma and Chronic Obstructive Pulmonary Disease (COPD) | Biotech Hunter | Biotech Hunter